*.- PharmaMar will present a study on the efficacy of Yondelis® in women with ovarian cancer at the European Society of Gynecological Oncology (ESGO) congress
*.- PharmaMar will organize a satellite symposium in which there will be a debate on whether quality of life of ovarian cancer patients is a key factor in the taking of decisions
Madrid, November 3rd, 2017.- PharmaMar (MSE:PHM) will announce the data obtained from a Phase IV clinical trial of its antitumor compound of marine origin, Yondelis®, during the European Society of Gynecological Oncology Congress (ESGO), that will be held from the 4th to the 7th of November in Vienna.
...
Saturday, November 4, 2017
13:00 -14:30
Hall B
THE KEY ROLE OF QUALITY OF LIFE IN THE LONG-DISTANCE RACE OF OVARIAN CANCER
Symposium Organized by: PharmaMar
CHAIR: Andreas Du Bois, Germany
13:00 WELCOME AND INTRODUCTION
Andreas Du Bois, Germany
Andreas Du Bois, Germany
13:05 SETTING THE SCENE: QUALITY OF LIFE IN OVARIAN CANCER, IS IT A KEY FACTOR FOR OUR DECISION MAKING?
Felix Hilpert, Germany
Felix Hilpert, Germany
13:25 BEING PRACTICAL
Case 1: Isabelle Ray-Coquard , France
Case 2: Nicoletta Colombo, Italy
Case 3: Christian Marth, Austria
Case 2: Nicoletta Colombo, Italy
Case 3: Christian Marth, Austria
14.25 CLOSING AND REMARKS
Andreas Du Bois, Germany
Andreas Du Bois, Germany